FCGR2A and irritable bowel syndrome: Both expression levels were negatively related to clinical characteristics of IBS patients, including BMI, weight, fat intake, IBSQOL, and the IBS severity score (Fig. 5e, p  < 0.001), suggesting that APOD and FCGR2A can be protective factors for IBS patients.